This series is jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC, and is supported by an educational grant from the National Marrow Donor Program®.
Access all four online CME programs
Navigating the Therapeutic Pathways for AML and MDS
Description
The optimal treatment algorithm for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is highly variable and complex and must be individualized. These CME-certified programs will explore the current state-of-the-art AML and MDS treatments. In these sessions, you will learn the role of risk stratification in treatment decision-making, outcomes for various therapeutic options, such as chemotherapy and transplantation, as well as the latest information about clinical trials. Special clinical issues in AML and MDS will be discussed, such as refractory disease and the role of novel molecular diagnostics.
Access individual programs:
Series Part 1:
Incorporating Molecular Data into Risk Stratification for AML
Steven Devine, M.D.
The Ohio State University
Columbus, Ohio
Series Part 2:
The Role of Allogeneic Hematopoietic Cell Transplantation in AML
Frederick Appelbaum, M.D.
University of Washington School of Medicine
Seattle, Washington
Series Part 3:
Options for High Risk AML and MDS
Daniel Weisdorf, M.D.
University of Minnesota
Minneapolis, Minnesota
Series Part 4:
Advances in AML/MDS: The Role of Multi-center Clinical TrialsDennis Confer, M.D.
National Marrow Donor Program
Minneapolis, Minnesota
Questions
If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail rryan@nmdp.org.